Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) FCF Margin: 2023-2025

Historic FCF Margin for Immunome (IMNM) over the last 2 years, with Jun 2025 value amounting to -1,252.95%.

  • Immunome's FCF Margin fell 16408.00% to -1,252.95% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,476.83%, marking a year-over-year decrease of 86914.00%. This contributed to the annual value of -1,304.80% for FY2024, which is 124488.00% down from last year.
  • Per Immunome's latest filing, its FCF Margin stood at -1,252.95% for Q2 2025, which was up 35.36% from -1,938.48% recorded in Q1 2025.
  • Immunome's FCF Margin's 5-year high stood at 1,013.11% during Q1 2023, with a 5-year trough of -1,938.48% in Q1 2025.
  • Over the past 3 years, Immunome's median FCF Margin value was -1,157.94% (recorded in 2024), while the average stood at -821.36%.
  • Data for Immunome's FCF Margin shows a maximum YoY tumbled of 230,893bps (in 2024) over the last 5 years.
  • Immunome's FCF Margin (Quarterly) stood at -465.45% in 2023, then tumbled by 111,184bps to -1,577.28% in 2024, then tumbled by 16,408bps to -1,252.95% in 2025.
  • Its FCF Margin was -1,252.95% in Q2 2025, compared to -1,938.48% in Q1 2025 and -1,577.28% in Q4 2024.